%0 Journal Article
%A Pennings, Elise R A
%A Thielen, Frederick W
%A Broussais, Florence
%A Delgado, Julio
%A Jaeger, Ulrich
%A Sanges, Carmen
%A Cabrerizo, Yolanda
%A Roux-Opstaele, Lutgart
%A Dreuillet, Caroline
%A Gonzalez-Marcano, Eglys
%A Millán, Olga
%A Huber, Barbara
%A Clavreul, Solène
%A Bolaños, Natacha
%A Nier, Samantha
%A Mihályová, Jana
%A Hájek, Roman
%A Horňáková, Michaela
%A Doeswijk, Robin
%A Thieblemont, Catherine
%A Hudecek, Michael
%A Uyl-de Groot, Carin A
%A Kersten, Marie José
%T The European CAR-T map-Current status and future directions to improve access to CAR T-cell therapy for hematologic malignancies.
%J HemaSphere
%V 10
%N 3
%@ 2572-9241
%C Hoboken
%I John Wiley & Sons Ltd.
%M DKFZ-2026-00560
%P e70306
%D 2026
%Z #NCTZFB9#
%X Despite its great promise, implementation of CAR-T therapy-a personalized, logistically complex, and expensive treatment-remains challenging, hampering patient access across and within countries. Since 2018, six products have been centrally approved in Europe (i.e., the European Economic Area; EU-approved) for 15 hematologic malignancy indications. To better understand patient access to EU-approved commercial CAR-T therapy, we evaluated the current status in all 30 countries where EU-approval is valid plus the UK, addressing economic, clinical, and organizational aspects, and identifying challenges and strategies for improvement. A two-step approach was used, complementing data from marketing authorization holders (4/4 responded) with country-specific insights from clinical experts obtained via an online survey (30/31 responded). In August 2024, 26
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:41799248
%2 pmc:PMC12961523
%R 10.1002/hem3.70306
%U https://inrepo02.dkfz.de/record/310364